Constellation Pharmaceuticals, Inc.

MorphoSys AG may not have added much more detail about its closely-watched myelofibrosis candidate pelabresib at the American Society of Hematology meeting but as the doors closed at the San Diego co

While MorphoSys AG CEO Jean-Paul Kress believes the German biotech has a blockbuster on its hands with pelabresib, the firm could still have a tricky time ahead with regulators following the release

After posting a solid, if unspectacular, set of financials for the second quarter, MorphoSys AG has placed its focus firmly on the German biotech’s myelofibrosis candidate pelabresib ahead of a keen

MorphoSys AG is refocusing efforts on its mid- to late-stage oncology pipeline, including its myelofibrosis candidate pelabresib, after a year of ups and downs that culminated in cost-cutting measure